Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”

R Eychenne, M Chérel, F Haddad, F Guérard… - Pharmaceutics, 2021 - mdpi.com
Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Bismuth-213 for targeted radionuclide therapy: from atom to bedside

S Ahenkorah, I Cassells, CM Deroose, T Cardinaels… - Pharmaceutics, 2021 - mdpi.com
In contrast to external high energy photon or proton therapy, targeted radionuclide therapy
(TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and …

Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors

MI Khan, F Batool, R Ali, W Wang, S Li, G Wang… - Coordination Chemistry …, 2022 - Elsevier
Existing anticancer therapeutic modalities in clinical settings lack efficacy and fail to
completely cure cancers. Clearly understandable and mechanistic approaches are …

Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging system

R Peter, BM Sandmaier, MP Dion, SHL Frost… - Scientific reports, 2022 - nature.com
Targeted radiopharmaceutical therapy with alpha-particle emitters (αRPT) is advantageous
in cancer treatment because the short range and high local energy deposition of alpha …

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells

X Liu, L Luan, X Liu, D Jiang, J Deng, J Xu… - Frontiers in …, 2023 - frontiersin.org
Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous
tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies …

Evaluation of [89Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer

M Ducharme, L Hall, W Eckenroad… - Molecular …, 2023 - ACS Publications
One of the most aggressive forms of breast cancer involves the overexpression of human
epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in∼ 25% of all breast …

Site-specific Radiohalogenation of a HER2-targeted single-domain antibody fragment using a Novel Residualizing Prosthetic agent

Y Feng, SM Sarrett, RL Meshaw… - Journal of medicinal …, 2022 - ACS Publications
Because of their rapid tumor accumulation and normal tissue clearance, single-domain
antibody fragments (sdAbs) are an attractive vehicle for developing radiotherapeutics …

[HTML][HTML] 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals

S Ahenkorah, E Murce, C Cawthorne, JP Ketchemen… - Theranostics, 2022 - ncbi.nlm.nih.gov
Background: Radiolabeled somatostatin analogues (eg [68 Ga] Ga-DOTATATE and [177 Lu]
Lu-DOTATATE) have been used to diagnose, monitor, and treat neuroendocrine tumour …

86Y-labeled albumin-binding fibroblast activation protein inhibitor for late-time-point cancer diagnosis

J Ding, M Xu, J Chen, P Zhang, L Huo… - Molecular …, 2022 - ACS Publications
Fibroblast activation protein inhibitor (FAPI) is a novel quinoline-based radiopharmaceutical
that has theranostic potential, yet the limited tumor retention hinders late-time diagnosis and …

Effective treatment of human breast carcinoma xenografts with single-dose 211At-labeled anti-HER2 single-domain antibody fragment

Y Feng, R Meshaw, XG Zhao, S Jannetti… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy,
particularly with 211At, because of their rapid accumulation in tumor and clearance from …